Alphina Therapeutics Welcomes Marc Damelin, Ph.D. to Its Team
Marc Damelin, Ph.D., has joined Alphina Therapeutics as the new Chief Scientific Officer. This appointment comes as the biotechnology firm enhances its commitment to developing innovative treatments for cancer, specifically through its leading NAMPT inhibitor program.
Dr. Damelin's Extensive Experience
Dr. Damelin brings over 17 years of profound expertise in the field of oncology drug discovery and development to his new role. He has held several key leadership positions in renowned oncology-focused companies, allowing him to contribute significantly to numerous platform technologies and successful clinical compounds.
Focus on Best-in-Class NAMPT Inhibitors
Alphina Therapeutics stands out in the biopharmaceutical landscape with its unique approach to NAMPT inhibition. The company applies an innovative synthetic lethality strategy that not only boosts the efficacy of its small molecules but also improves the safety profile of its therapies compared to previous NAMPT inhibitors.
Personalized Treatment Opportunities
A vital aspect of Alphina’s strategy is its proprietary patient selection assay. This advanced tool helps identify patients with non-small cell lung cancer, small cell lung cancer, colorectal cancer, ovarian cancer, and other solid tumors who are most likely to respond positively to their drug candidates. By pinpointing these patients, Alphina aims to enhance therapeutic outcomes.
Marc's Vision for the Future
Nick Galli, CEO of Alphina Therapeutics, expressed optimism regarding Dr. Damelin’s appointment. He highlighted Dr. Damelin's brilliance in drug development and his potential to lead their NAMPT program successfully. Galli stated, “We are excited to welcome Marc to our leadership team and look forward to leveraging his extensive experience.”
Leadership Role at Mersana Therapeutics
Before joining Alphina, Dr. Damelin was Vice President and Head of Biology at Mersana Therapeutics, where he led significant advancements in antibody-drug conjugate (ADC) platforms. His efforts there yielded three partnerships generating substantial upfront payments, reflecting his capability to drive valuable collaborations in the biotech sector.
Decade at Pfizer's Oncology Research Unit
His decade-long tenure at Pfizer’s Oncology Research Unit is notable, where Dr. Damelin spearheaded multiple projects that transitioned into clinical trials. His leadership in ADC discovery further attests to his specialized knowledge and commitment to advancing cancer therapies.
Looking Ahead with Alphina Therapeutics
Dr. Damelin expressed enthusiasm for his new role at Alphina, recognizing the company's innovative approach. He remarked, “Alphina has significant potential to revolutionize cancer care by creating compounds that overcome limitations faced by previous NAMPT inhibitors.” His vision aligns with Alphina’s commitment to maximizing therapeutic success and patient benefit through tailored treatment strategies.
About Alphina Therapeutics
Alphina Therapeutics is dedicated to pioneering a best-in-class small molecule inhibitor of NAMPT aimed at treating diverse solid tumors. Founded by leading scientists and supported by a robust investor community, the company is developing a proprietary assay that identifies patients whose tumors exhibit specific vulnerabilities, making them ideal candidates for treatment with Alphina’s therapies. Their approach positions them well within the competitive landscape of oncology.
Frequently Asked Questions
What is the mission of Alphina Therapeutics?
Alphina Therapeutics is committed to developing innovative therapies for cancer treatment, focusing on creating best-in-class small molecule inhibitors.
Who is Marc Damelin, Ph.D.?
Marc Damelin, Ph.D. is the new Chief Scientific Officer at Alphina Therapeutics, bringing extensive experience in oncology drug development.
What is the significance of the NAMPT inhibitor program?
The NAMPT inhibitor program is essential for Alphina as it aims to provide effective treatment options for solid tumor indications by utilizing innovative therapeutic strategies.
How does Alphina select patients for its drug candidates?
Alphina has developed a proprietary patient selection assay that identifies candidates most likely to benefit from their NAMPT inhibitors based on specific tumor characteristics.
What previous roles has Dr. Damelin held?
Before joining Alphina, Dr. Damelin served as Vice President at Mersana Therapeutics and held key roles at Pfizer's Oncology Research Unit.
